INT3768

From wiki-pain
Jump to: navigation, search
Context Info
Confidence 0.59
First Reported 1977
Last Reported 2010
Negated 1
Speculated 0
Reported most in Abstract
Documents 16
Total Number 16
Disease Relevance 4.96
Pain Relevance 5.52

This is a graph with borders and nodes. Maybe there is an Imagemap used so the nodes may be linking to some Pages.

cell differentiation (ANPEP) cytosol (ANPEP) peptidase activity (ANPEP)
plasma membrane (ANPEP) cytoplasm (ANPEP)
Anatomy Link Frequency
plasma 2
liver 1
lymphocytes 1
brain 1
neutrophils 1
ANPEP (Homo sapiens)
Pain Link Frequency Relevance Heat
Enkephalin 24 100.00 Very High Very High Very High
cINOD 8 99.98 Very High Very High Very High
opioid receptor 39 99.96 Very High Very High Very High
diclofenac 56 99.80 Very High Very High Very High
agonist 3 98.88 Very High Very High Very High
Endogenous opioid 8 98.16 Very High Very High Very High
Analgesic 45 96.60 Very High Very High Very High
Morphine 15 95.76 Very High Very High Very High
Inflammation 41 94.88 High High
Pain management 6 93.88 High High
Disease Link Frequency Relevance Heat
INFLAMMATION 49 99.86 Very High Very High Very High
Leukemia 2 99.60 Very High Very High Very High
Cancer 25 98.52 Very High Very High Very High
Disease 29 96.40 Very High Very High Very High
Pain 23 93.52 High High
Constipation 1 89.32 High High
Impaired Glucose Tolerance 22 89.04 High High
Respiratory Failure 1 88.64 High High
Angina 1 75.00 Quite High
Appetite Loss 8 73.92 Quite High

Sentences Mentioned In

Key: Protein Mutation Event Anatomy Negation Speculation Pain term Disease term
Therefore, inhibition of APN/CD13 may lead to the development of anti-cancer and anti-inflammatory drugs.
Negative_regulation (inhibition) of APN associated with inflammation, cancer and cinod
1) Confidence 0.59 Published 2006 Journal Med Res Rev Section Abstract Doc Link 16216010 Disease Relevance 0.62 Pain Relevance 0.23
On the other hand, the retro-inverso modification led to a slight improvement in the inhibition of DAP and APN, in the first series of inhibitors, while the inverse result occurred in the second series.
Negative_regulation (inhibition) of APN
2) Confidence 0.57 Published 1988 Journal J. Med. Chem. Section Abstract Doc Link 2900898 Disease Relevance 0 Pain Relevance 0.19
Preincubation of neutrophils with MENK, but not with the synthetic agonist of the mu (DAGO) or the delta (DPDPE) opioid receptor, down-regulated the APN activity.
Neg (not) Negative_regulation (down-regulated) of APN in neutrophils associated with agonist, opioid receptor and enkephalin
3) Confidence 0.51 Published 1999 Journal Immunopharmacology Section Abstract Doc Link 9950265 Disease Relevance 0 Pain Relevance 0.84
Natural and synthetic inhibitors of APN activity have been characterized.
Negative_regulation (inhibitors) of APN
4) Confidence 0.51 Published 2006 Journal Med Res Rev Section Abstract Doc Link 16216010 Disease Relevance 0.62 Pain Relevance 0.21
Aminopeptidase-N/CD13 (EC 3.4.11.2) inhibitors: chemistry, biological evaluations, and therapeutic prospects.
Negative_regulation (inhibitors) of Aminopeptidase-N/CD13
5) Confidence 0.43 Published 2006 Journal Med Res Rev Section Title Doc Link 16216010 Disease Relevance 0.56 Pain Relevance 0.19
Therefore, inhibition of APN/CD13 may lead to the development of anti-cancer and anti-inflammatory drugs.
Negative_regulation (inhibition) of CD13 associated with inflammation, cancer and cinod
6) Confidence 0.42 Published 2006 Journal Med Res Rev Section Abstract Doc Link 16216010 Disease Relevance 0.62 Pain Relevance 0.23
Various physiological functions of Bestatin have been identified, viz.: (1) an immunomodifier for enhancing the proliferation of normal human bone marrow granulocyte–macrophage progenitor cells to form CFU-GM colonies; Bestatin exerts a direct stimulating effect on lymphocytes via its fixation on the cell surface and an indirect effect on monocytes via aminopeptidase B inhibition of tuftsin catabolism; (2) an immunorestorator and curative or preventive agent for spontaneous tumor; Bestatin alone or its combination with chemicals can prolongate the disease-free interval and survival period in adult acute or chronic leukemia, therefore, it was primarily marketed in 1987 in Japan as an anticancer drug and servers as the only marketed inhibitor of Aminopeptidase N (APN/CD13) to cure leukemia to date; (3) a pan-hematopoietic stimulator and restorator; Bestatin promotes granulocytopoiesis and thrombocytopoiesis in vitro and restores them in myelo-hypoplastic men; (4) an inhibitor of several natural opioid peptides.
Negative_regulation (inhibitor) of CD13 in lymphocytes associated with leukemia, cancer, disease and opioid
7) Confidence 0.42 Published 2010 Journal Frontiers in Neuroscience Section Abstract Doc Link PMC2903224 Disease Relevance 0.39 Pain Relevance 0.26
Peptide retro-inverso modification was applied to the complete hydroxamate inhibitors of the three zinc metallopeptidases (neutral endopeptidase 24-11 (NEP, EC 3.4.24.11), aminopeptidase N (APN, EC 3.4.11.2), and a dipeptidylaminopeptidase (DAP) involved in the in vitro enkephalin degradation by brain tissues.
Negative_regulation (inhibitors) of APN in brain associated with enkephalin
8) Confidence 0.42 Published 1988 Journal J. Med. Chem. Section Abstract Doc Link 2900898 Disease Relevance 0 Pain Relevance 0.21
All acidic non-steroidal anti-inflammatory drugs suppress the activity of microsomal cyclo-oxygenase of arachidonic acid; therefore, these drugs are equipotent inhibitors of prostaglandin and thromboxane generation.
Negative_regulation (suppress) of microsomal cyclo-oxygenase associated with inflammation and cinod
9) Confidence 0.41 Published 1977 Journal Naunyn Schmiedebergs Arch. Pharmacol. Section Abstract Doc Link 859658 Disease Relevance 0.19 Pain Relevance 0.14
The discovery that the endogenous opioid peptides, enkephalins, are inactivated by two metallopeptidases, neutral endopeptidase and aminopeptidase N, which can be blocked by synthetic dual inhibitors, represents a promising way to develop 'physiological' analgesics devoid of morphine side effects.
Negative_regulation (blocked) of aminopeptidase N associated with analgesic, endogenous opioid, enkephalin and morphine
10) Confidence 0.39 Published 2007 Journal Expert Opin. Ther. Targets Section Abstract Doc Link 17227231 Disease Relevance 0.52 Pain Relevance 1.34
This review provides an update on the biological and pharmacological profiles of known natural and synthetic APN inhibitors.
Negative_regulation (inhibitors) of APN
11) Confidence 0.38 Published 2006 Journal Med Res Rev Section Abstract Doc Link 16216010 Disease Relevance 0.58 Pain Relevance 0.22
Both alanyl-naphthylamidase and enkephalin degradation were optimal at pH 7.0 to 7.5 and were inhibited by aminopeptidase inhibitors amastatin (IC50 = 20 nM), bestatin (4-7 microM) and puromycin (30-35 microM).
Negative_regulation (inhibited) of alanyl-naphthylamidase associated with enkephalin
12) Confidence 0.34 Published 1990 Journal Biochem. Pharmacol. Section Abstract Doc Link 1974424 Disease Relevance 0 Pain Relevance 0.69
Only 13% (4/32) of pts. showed a decrease in phase angle in spite of APN.
Negative_regulation (decrease) of APN
13) Confidence 0.32 Published 2010 Journal BMC Cancer Section Body Doc Link PMC2841666 Disease Relevance 0.20 Pain Relevance 0
The inhibition of the enzyme aminopeptidase N (CD13) by diclofenac corresponds to the lower plasma concentrations of several neutral amino acids such as L-isoleucine, L-threonine, and L-leucine.
Negative_regulation (inhibition) of CD13 in plasma associated with diclofenac
14) Confidence 0.08 Published 2009 Journal PLoS ONE Section Body Doc Link PMC2643463 Disease Relevance 0.26 Pain Relevance 0.28
The inhibition of the enzyme aminopeptidase N (CD13) by diclofenac corresponds to the lower plasma concentrations of several neutral amino acids such as L-isoleucine, L-threonine, and L-leucine.
Negative_regulation (inhibition) of aminopeptidase N in plasma associated with diclofenac
15) Confidence 0.08 Published 2009 Journal PLoS ONE Section Body Doc Link PMC2643463 Disease Relevance 0.26 Pain Relevance 0.28
Nifedipin treatment caused no induction or inhibition of nonspecific microsomal hepatic oxidase activity in the patients so the drug may be expected to have no substantial effect on pharmacokinetics, and hence, efficacy, of combined drugs that are eliminated by oxidation inside the liver.
Negative_regulation (inhibition) of microsomal hepatic oxidase in liver
16) Confidence 0.03 Published 1989 Journal Kardiologiia Section Abstract Doc Link 2770079 Disease Relevance 0.15 Pain Relevance 0.19

General Comments

This test has worked.

Personal tools
Namespaces

Variants
Actions
Navigation
Toolbox